Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851371 | 0.90 | ALDH1A1 (0.40) | CES2CES1TP53LMNAKMT2A | |
| SCHEMBL5849615 | 0.85 | MAPT (0.42) | CES2CES1TP53LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL5850101 | 0.84 | MAPT (0.41) | CES2CES1TP53LMNAKMT2A | |
| SCHEMBL5849533 | 0.82 | RAB9A (0.40) | KMT2ARAB9APARP1SMN1; SMN2 | |
| SCHEMBL5850125 | 0.82 | ACKR3 (0.37) | CES2CES1LMNARAB9AACKR3 | |
| SCHEMBL5851877 | 0.80 | ACKR3 (0.36) | CES2CES1AKT1ACKR3 | |
| SCHEMBL5849717 | 0.80 | ACKR3 (0.37) | CES2CES1RAB9ASMN1; SMN2ACKR3 | |
| Hydrochloric Acid SCHEMBL5851326 | 0.80 | MEN1 (0.39) | CES2CES1LMNAKMT2ARAB9A | |
| SCHEMBL5849411 | 0.79 | ITGB3 (0.37) | CES2CES1KMT2AAKT1RAB9A | |
| SCHEMBL5850318 | 0.75 | MAPT (0.40) | CES2CES1TP53LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984646-B2 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALHCARE AG (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | MAPK1, MAPK3, MAP3K1 | CES2 4391/4885CES1 1896/4885TP53 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.